Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)

SHE:002727 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	3,448	3,418	3,676	3,512	2,235	1,624
Short-Term Investments	-	-	219.66	-	-	1,433
Trading Asset Securities	-	-	-	8.36	297.3	-
Cash & Short-Term Investments	3,448	3,418	3,895	3,520	2,532	3,057
Cash Growth	-11.73%	-12.26%	10.66%	39.00%	-17.16%	27.91%
Accounts Receivable	1,966	1,613	1,555	1,776	1,376	846.91
Other Receivables	298.17	319.49	313.3	307.29	206.63	150.18
Receivables	2,264	1,932	1,868	2,083	1,583	997.09
Inventory	3,943	4,088	3,853	3,387	3,317	2,194
Prepaid Expenses	-	3.49	1.03	0.14	0.16	0.01
Other Current Assets	340.9	270.29	275.63	467.06	260.12	469.49
Total Current Assets	9,996	9,712	9,893	9,458	7,692	6,718
Property, Plant & Equipment	3,814	3,956	3,951	3,994	4,080	690.52
Long-Term Investments	134.23	136.52	143.26	352.46	107.22	83.64
Goodwill	1,983	1,983	1,650	1,397	1,380	1,102
Other Intangible Assets	193.11	196.86	178.08	165.67	122.89	122.88
Long-Term Deferred Tax Assets	96.22	93.7	88.94	94.11	58.46	27.62
Long-Term Deferred Charges	703.58	724.03	661.17	629.9	590.75	530.72
Other Long-Term Assets	28.7	29	82.31	88.59	305.71	52.71
Total Assets	16,948	16,830	16,647	16,179	14,337	9,328
Accounts Payable	5,041	4,916	4,339	4,329	3,806	2,876
Accrued Expenses	236.94	539.54	681.48	518.75	295.38	328.78
Short-Term Debt	549.84	495.57	468.6	402.57	127.7	60.06
Current Portion of Long-Term Debt	959.75	-	1.8	0.2	4.02	-
Current Portion of Leases	-	1,005	975.88	932.77	1,012	-
Current Income Taxes Payable	211.25	53.62	81.37	197.86	118.4	54.53
Current Unearned Revenue	102.96	116.9	113.72	156.61	105.18	67.15
Other Current Liabilities	577.73	504.61	537.55	339.23	415.09	145.71
Total Current Liabilities	7,679	7,631	7,200	6,877	5,884	3,532
Long-Term Debt	135.08	-	-	1.8	35.08	-
Long-Term Leases	1,445	1,531	1,552	1,757	1,729	-
Long-Term Unearned Revenue	18.13	11.55	14.54	12.15	13.34	15.79
Long-Term Deferred Tax Liabilities	3.53	3.55	3.93	4.05	3.56	-
Total Liabilities	9,280	9,177	8,770	8,652	7,665	3,548
Common Stock	585.6	585.6	596.01	596.02	596.18	595.31
Additional Paid-In Capital	2,019	2,019	2,144	2,147	2,157	2,097
Retained Earnings	5,047	4,886	5,011	4,700	3,869	3,126
Treasury Stock	-150	-	-4.24	-22.69	-46.86	-53.37
Comprehensive Income & Other	-	-	-	6.19	2.93	0.32
Total Common Equity	7,501	7,491	7,746	7,426	6,578	5,765
Minority Interest	166.8	162.27	131.04	101.44	94.8	15.09
Shareholders' Equity	7,668	7,653	7,877	7,528	6,673	5,780
Total Liabilities & Equity	16,948	16,830	16,647	16,179	14,337	9,328
Total Debt	3,089	3,031	2,998	3,094	2,908	60.06
Net Cash (Debt)	358.57	386.58	896.84	425.94	-375.58	2,997
Net Cash Growth	-52.91%	-56.90%	110.56%	-	-	57.15%
Net Cash Per Share	0.61	0.65	1.50	0.72	-0.63	5.23
Filing Date Shares Outstanding	574.13	585.6	596.01	596.02	596.18	595.31
Total Common Shares Outstanding	574.13	585.6	596.01	596.02	596.18	595.31
Working Capital	2,317	2,080	2,693	2,581	1,809	3,186
Book Value Per Share	13.07	12.79	13.00	12.46	11.03	9.68
Tangible Book Value	5,325	5,311	5,918	5,863	5,075	4,540
Tangible Book Value Per Share	9.28	9.07	9.93	9.84	8.51	7.63
Buildings	-	892.7	894.92	785.07	741.03	576.73
Machinery	-	447.47	416.9	385.35	350.85	293.68
Construction In Progress	-	35.79	9.81	3.87	25.47	15.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.